{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:22Z","timestamp":1793505622287,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mood disorders (depression, bipolar disorders) are prevalent and disabling. They are also highly co-morbid with other psychiatric disorders. Currently there are no objective measures, such as blood tests, used in clinical practice, and available treatments do not work in everybody. The development of blood tests, as well as matching of patients with existing and new treatments, in a precise, personalized and preventive fashion, would make a significant difference at an individual and societal level. Early pilot studies by us to discover blood biomarkers for mood state were promising [1], and validated by others [2]. Recent work by us has identified blood gene expression biomarkers that track suicidality, a tragic behavioral outcome of mood disorders, using powerful longitudinal within-subject designs, validated them in suicide completers, and tested them in independent cohorts for ability to assess state (suicidal ideation), and ability to predict trait (future hospitalizations for suicidality) [3\u20136]. These studies showed good reproducibility with subsequent independent genetic studies [7]. More recently, we have conducted such studies also for pain [8], for stress disorders [9], and for memory\/Alzheimer\u2019s Disease [10]. We endeavored to use a similar comprehensive approach to identify more definitive biomarkers for mood disorders, that are transdiagnostic, by studying mood in psychiatric disorders patients. First, we used a longitudinal within-subject design and whole-genome gene expression approach to discover biomarkers which track mood state in subjects who had diametric changes in mood state from low to high, from visit to visit, as measured by a simple visual analog scale that we had previously developed (SMS-7). Second, we prioritized these biomarkers using a convergent functional genomics (CFG) approach encompassing in a comprehensive fashion prior published evidence in the field. Third, we validated the biomarkers in an independent cohort of subjects with clinically severe depression (as measured by Hamilton Depression Scale, (HAMD)) and with clinically severe mania (as measured by the Young Mania Rating Scale (YMRS)). Adding the scores from the first three steps into an overall convergent functional evidence (CFE) score, we ended up with 26 top candidate blood gene expression biomarkers that had a CFE score as good as or better than SLC6A4, an empirical finding which we used as a de facto positive control and cutoff. Notably, there was among them an enrichment in genes involved in circadian mechanisms. We further analyzed the biological pathways and networks for the top candidate biomarkers, showing that circadian, neurotrophic, and cell differentiation functions are involved, along with serotonergic and glutamatergic signaling, supporting a view of mood as reflecting energy, activity and growth. Fourth, we tested in independent cohorts of psychiatric patients the ability of each of these 26 top candidate biomarkers to assess state (mood (SMS-7), depression (HAMD), mania (YMRS)), and to predict clinical course (future hospitalizations for depression, future hospitalizations for mania). We conducted our analyses across all patients, as well as personalized by gender and diagnosis, showing increased accuracy with the personalized approach, particularly in women. Again,\u00a0using SLC6A4 as the cutoff, twelve top biomarkers had the strongest overall evidence for tracking and predicting depression after all four steps: NRG1, DOCK10, GLS, PRPS1, TMEM161B, GLO1, FANCF, HNRNPDL, CD47, OLFM1, SMAD7, and SLC6A4. Of them, six had the strongest overall evidence for tracking and predicting both depression and mania, hence bipolar mood disorders. There were also two biomarkers (RLP3 and SLC6A4) with the strongest overall evidence for mania. These panels of biomarkers have practical implications for distinguishing between depression and bipolar disorder. Next, we evaluated the evidence for our top biomarkers being targets of existing psychiatric drugs, which permits matching patients to medications in a targeted fashion, and the measuring of response to treatment. We also used the biomarker signatures to bioinformatically identify new\/repurposed candidate drugs. Top drugs of interest as potential new antidepressants were pindolol, ciprofibrate, pioglitazone and adiphenine, as well as the natural compounds asiaticoside and chlorogenic acid. The last 3 had also been identified by our previous suicidality studies. Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.<\/jats:p>","DOI":"10.1038\/s41380-021-01061-w","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T21:02:29Z","timestamp":1617829349000},"page":"2776-2804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-5789","authenticated-orcid":false,"given":"H.","family":"Le-Niculescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Roseberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-3839","authenticated-orcid":false,"given":"S. S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-9569","authenticated-orcid":false,"given":"D. F.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-3475","authenticated-orcid":false,"given":"P. L.","family":"Phalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Voegtline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Niculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/mp.2008.11","volume":"14","author":"H Le-Niculescu","year":"2009","unstructured":"Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry. 2009;14:156\u201374.","journal-title":"Mol Psychiatry"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jad.2014.04.030","volume":"164","author":"S Keri","year":"2014","unstructured":"Keri S, Szabo C, Kelemen O. Blood biomarkers of depression track clinical changes during cognitive-behavioral therapy. J Affect Disord. 2014;164:118\u201322.","journal-title":"J Affect Disord"},{"key":"1061_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/mp.2013.95","volume":"18","author":"H Le-Niculescu","year":"2013","unstructured":"Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N, et al. Discovery and validation of blood biomarkers for suicidality. Mol Psychiatry. 2013;18:1249\u201364.","journal-title":"Mol Psychiatry"},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/mp.2015.112","volume":"20","author":"AB Niculescu","year":"2015","unstructured":"Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, et al. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. Mol Psychiatry. 2015;20:1266\u201385.","journal-title":"Mol Psychiatry"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/mp.2016.31","volume":"21","author":"DF Levey","year":"2016","unstructured":"Levey DF, Niculescu EM, Le-Niculescu H, Dainton HL, Phalen PL, Ladd TB, et al. Towards understanding and predicting suicidality in women: biomarkers and clinical risk assessment. Mol Psychiatry. 2016;21:768\u201385.","journal-title":"Mol Psychiatry"},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/mp.2017.128","volume":"22","author":"AB Niculescu","year":"2017","unstructured":"Niculescu AB, Le-Niculescu H, Levey DF, Phalen PL, Dainton HL, Roseberry K, et al. Precision medicine for suicidality: from universality to subtypes and personalization. Mol Psychiatry. 2017;22:1250\u201373.","journal-title":"Mol Psychiatry"},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41380-019-0465-6","volume":"25","author":"AB Niculescu","year":"2020","unstructured":"Niculescu AB, Le-Niculescu H. Convergence of recent GWAS data for suicidality with previous blood biomarkers: independent reproducibility using independent methodologies in independent cohorts. Mol Psychiatry. 2020;25:19\u201321.","journal-title":"Mol Psychiatry"},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41380-018-0345-5","volume":"24","author":"AB Niculescu","year":"2019","unstructured":"Niculescu AB, Le-Niculescu H, Levey DF, Roseberry K, Soe KC, Rogers J, et al. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019;24:501\u201322.","journal-title":"Mol Psychiatry"},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41380-019-0370-z","volume":"25","author":"H Le-Niculescu","year":"2019","unstructured":"Le-Niculescu H, Roseberry K, Levey DF, Rogers J, Kosary K, Prabha S, et al. Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs. Mol Psychiatry. 2019;25:918\u201338.","journal-title":"Mol Psychiatry"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41380-019-0602-2","volume":"25","author":"AB Niculescu","year":"2019","unstructured":"Niculescu AB, Le-Niculescu H, Roseberry K, Wang S, Hart J, Kaur A, et al. Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2019;25:1651\u201372.","journal-title":"Mol Psychiatry"},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/npp.2016.228","volume":"42","author":"AB Niculescu","year":"2017","unstructured":"Niculescu AB, Le-Niculescu H. Dissecting suicidality using a combined genomic and clinical approach. Neuropsychopharmacology. 2017;42:360.","journal-title":"Neuropsychopharmacology"},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ajmg.b.30404","volume":"141B","author":"AB Niculescu","year":"2006","unstructured":"Niculescu AB, Lulow LL, Ogden CA, Le-Niculescu H, Salomon DR, Schork NJ, et al. PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes. Am J Med Genet Part B, Neuropsychiatr Genet. 2006;141B:653\u201362.","journal-title":"Am J Med Genet Part B, Neuropsychiatr Genet"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cell.2009.08.031","volume":"139","author":"EE Zhang","year":"2009","unstructured":"Zhang EE, Liu AC, Hirota T, Miraglia LJ, Welch G, Pongsawakul PY, et al. A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell. 2009;139:199\u2013210.","journal-title":"Cell"},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/0748730412456367","volume":"27","author":"MJ McCarthy","year":"2012","unstructured":"McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. J Biol Rhythms. 2012;27:339\u201352.","journal-title":"J Biol Rhythms"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/ajmg.b.30707","volume":"147B","author":"H Le-Niculescu","year":"2008","unstructured":"Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J, et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet Part B, Neuropsychiatr Genet. 2008;147B:134\u201366.","journal-title":"Am J Med Genet Part B, Neuropsychiatr Genet"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jpsychires.2010.04.011","volume":"44","author":"R Belzeaux","year":"2010","unstructured":"Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res. 2010;44:1205\u201313.","journal-title":"J Psychiatr Res"},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/mp.2009.117","volume":"16","author":"SM Kurian","year":"2011","unstructured":"Kurian SM, Le-Niculescu H, Patel SD, Bertram D, Davis J, Dike C, et al. Identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry. 2011;16:37\u201358.","journal-title":"Mol Psychiatry"},{"key":"1061_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9570","volume":"6","author":"MJ Peters","year":"2015","unstructured":"Peters MJ, Joehanes R, Pilling LC, Schurmann C, Conneely KN, Powell J, et al. The transcriptional landscape of age in human peripheral blood. Nat Commun. 2015;6:8570.","journal-title":"Nat Commun"},{"key":"1061_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-4-215","volume":"6","author":"AB Niculescu","year":"2005","unstructured":"Niculescu AB. Genomic studies of mood disorders\u2014the brain as a muscle? Genome Biol. 2005;6:215.","journal-title":"Genome Biol"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1399-5618.2010.00882.x","volume":"12","author":"RD Beech","year":"2010","unstructured":"Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S, et al. Increased peripheral blood expression of electron transport chain genes in bipolar depression. Bipolar Disord. 2010;12:813\u201324.","journal-title":"Bipolar Disord"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neuron.2016.04.015","volume":"90","author":"RC Bagot","year":"2016","unstructured":"Bagot RC, Cates HM, Purushothaman I, Lorsch ZS, Walker DM, Wang J, et al. Circuit-wide transcriptional profiling reveals brain region-specific gene networks regulating depression susceptibility. Neuron. 2016;90:969\u201383.","journal-title":"Neuron"},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm.4386","volume":"23","author":"B Labonte","year":"2017","unstructured":"Labonte B, Engmann O, Purushothaman I, Menard C, Wang J, Tan C, et al. Sex-specific transcriptional signatures in human depression. Nat Med. 2017;23:1102\u201311.","journal-title":"Nat Med"},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fnmol.2016.00062","volume":"9","author":"M Huttenrauch","year":"2016","unstructured":"Huttenrauch M, Salinas G, Wirths O. Effects of long-term environmental enrichment on anxiety, memory, hippocampal plasticity and overall brain gene expression in C57BL6 mice. Front Mol Neurosci. 2016;9:62.","journal-title":"Front Mol Neurosci"},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2016.03.022","volume":"165","author":"GA Erikson","year":"2016","unstructured":"Erikson GA, Bodian DL, Rueda M, Molparia B, Scott ER, Scott-Van Zeeland AA, et al. Whole-genome sequencing of a healthy aging cohort. Cell. 2016;165:1002\u201311.","journal-title":"Cell"},{"key":"1061_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3233\/JAD-148009","volume":"45","author":"K Nho","year":"2015","unstructured":"Nho K, Ramanan VK, Horgusluoglu E, Kim S, Inlow MH, Risacher SL, et al. Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. J Alzheimers Dis. 2015;45:1197\u2013206.","journal-title":"J Alzheimers Dis"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/mp.2016.65","volume":"21","author":"S Rangaraju","year":"2016","unstructured":"Rangaraju S, Levey DF, Nho K, Jain N, Andrews KD, Le-Niculescu H, et al. Mood, stress and longevity: convergence on ANK3. Mol Psychiatry. 2016;21:1037\u201349.","journal-title":"Mol Psychiatry"},{"key":"1061_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4088\/JCP.v64n0209","volume":"64","author":"RM Hirschfeld","year":"2003","unstructured":"Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161\u201374.","journal-title":"J Clin Psychiatry"},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jad.2007.01.027","volume":"103","author":"M Berk","year":"2007","unstructured":"Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord. 2007;103:181\u20136.","journal-title":"J Affect Disord"},{"key":"1061_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","volume":"148","author":"R Chen","year":"2012","unstructured":"Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293\u2013307.","journal-title":"Cell"},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1152\/physiolgenomics.2000.4.1.83","volume":"4","author":"AB Niculescu 3rd","year":"2000","unstructured":"Niculescu AB 3rd, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genom. 2000;4:83\u201391.","journal-title":"Physiol Genom"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41588-019-0397-8","volume":"51","author":"EA Stahl","year":"2019","unstructured":"Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51:793\u2013803.","journal-title":"Nat Genet"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biopsych.2019.10.015","volume":"88","author":"JRI Coleman","year":"2020","unstructured":"Coleman JRI, Gaspar HA, Bryois J, Bipolar Disorder Working Group of the Psychiatric Genomics C, Major Depressive Disorder Working Group of the Psychiatric Genomics C, Breen G. The genetics of the mood disorder spectrum: genome-wide association analyses of more than 185,000 cases and 439,000 controls. Biol Psychiatry. 2020;88:169\u201384.","journal-title":"Biol Psychiatry"},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343\u201352.","journal-title":"Nat Neurosci"},{"key":"1061_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.biopsych.2019.10.014","volume":"87","author":"RF Chan","year":"2020","unstructured":"Chan RF, Turecki G, Shabalin AA, Guintivano J, Zhao M, Xie LY, et al. Cell type-specific methylome-wide association studies implicate neurotrophin and innate immune signaling in major depressive disorder. Biol Psychiatry. 2020;87:431\u201342.","journal-title":"Biol Psychiatry"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3389\/fgene.2019.00870","volume":"10","author":"IA Cook","year":"2019","unstructured":"Cook IA, Congdon E, Krantz DE, Hunter AM, Coppola G, Hamilton SP, et al. Time course of changes in peripheral blood gene expression during medication treatment for major depressive disorder. Front Genet. 2019;10:870.","journal-title":"Front Genet"},{"key":"1061_CR36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929\u201335.","journal-title":"Science"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01061-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01061-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01061-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:32:31Z","timestamp":1633944751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01061-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01061-w","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ABN is listed as inventor on a patent application filed by Indiana University. ABN and AS are co-founders, and SMK is a consultant to, MindX Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}